GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (FRA:1RV) » Definitions » Short Percentage of Float

Rhythm Pharmaceuticals (FRA:1RV) Short Percentage of Float


View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Rhythm Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, Rhythm Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rhythm Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's Short Percentage of Float falls into.


Rhythm Pharmaceuticals (FRA:1RV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (FRA:1RV) » Definitions » Short Percentage of Float
Comparable Companies
PNT SMMT CPRX SWTX PTCT VCYT HRMY BEAM ABCL MRUS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
RYTM:USA RYTM:Mexico 1RV:Germany
Address
222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Website
http://www.rhythmtx.com
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.

Rhythm Pharmaceuticals (FRA:1RV) Headlines

No Headlines